F2G, a developer of next-generation antifungal therapies, has selected Bruntwood SciTech’s Alderley Park life science and innovation campus as its new UK headquarters. The move consolidates the company’s existing operations in Eccles and MediaCity into a single, purpose-built laboratory facility.
The relocation sees F2G occupy nearly 3,000 sq ft of high-specification lab space within the fully let Mereside complex at Alderley Park, a hub designed to support the growth of life science businesses.
This strategic move follows F2G’s successful $100 million fundraising round in late 2024 and aligns with its accelerated development and regulatory ambitions. The company was recently visited by Professor Sir Chris Whitty, the UK’s Chief Medical Officer, who discussed the fungal disease landscape and the challenges facing antifungal drug research in the UK.
By moving to Alderley Park, F2G joins a growing ecosystem of life science and tech-focused organisations, including Medicines Discovery Catapult, CellCentric, Globachem Discovery, Evotec, SAP, and recent arrivals like Revvity. The company will also benefit from collaboration opportunities with businesses in the Alderley Park Life Sciences Accelerator and the Female Founders Incubator.
In addition to specialist lab space, F2G will gain access to Bruntwood SciTech’s shared scientific services and coworking labs, as well as a wide range of on-site amenities. These include cafes, meeting rooms, breakout spaces, a gym, sports facilities, cycle and shower hub, The Churchill Tree pub, and a 232-seat auditorium — all set within landscaped green spaces.
Kath Mackay, Chief Scientific Officer at Bruntwood SciTech, commented:
“F2G’s decision to base its UK operations at Alderley Park is a strong endorsement of what our campus offers to innovative life science companies. At this crucial stage in their growth, they recognised the value of a location that combines cutting-edge facilities, collaborative networks, and a strong local talent pool.
This new facility will provide F2G with the technical flexibility required to progress their clinical and preclinical pipeline. Alderley Park offers the infrastructure and ecosystem to accelerate pioneering science and support commercial readiness.”
Dr Mike Birch, Chief Operating Officer at F2G, added:
“We’re excited to become part of the Alderley Park community. This relocation to a modern, purpose-designed facility is a key milestone for us as we continue to discover and develop new antifungal therapies.
Being based at Alderley Park strengthens our relationships with existing partners and opens the door to new collaborations. It also enhances our ability to attract top talent and offers a dynamic and supportive working environment.”
